PRME Prime Medicine, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%
Returns
ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.63M | $2.98M |
| R&D expense | $160.64M | $155.29M |
| SG&A expense | $52.35M | $50.16M |
| Operating income | -$208.35M | -$202.47M |
| Income tax | $0 | $0 |
| Net income | -$201.14M | -$195.88M |
| EBITDA | -$201.03M | -$196.34M |
| EPS (basic) | -1.35 | -1.65 |
| EPS (diluted) | -1.35 | -1.65 |
| Weighted avg. shares (diluted) | 148.76M | 118.60M |
| Balance sheet | ||
| Cash & equivalents | $63.03M | $196.54M |
| Short-term investments | $114.65M | — |
| Current assets | $181.29M | $211.89M |
| PP&E, net | $20.57M | $24.40M |
| Total assets | $342.73M | $297.51M |
| Current liabilities | $37.45M | $37.96M |
| Total liabilities | $221.87M | $144.36M |
| Shareholders' equity | $120.87M | $153.15M |
| Shares outstanding | 180.51M | 131.16M |
| Cash flow statement | ||
| Operating cash flow | -$162.56M | -$122.86M |
| Capital expenditure | $4.53M | $7.29M |
| Free cash flow | -$167.09M | -$130.16M |
| Investing cash flow | -$108.76M | $68.46M |
| Financing cash flow | $151.51M | $195.88M |
| Depreciation & amortization | $7.32M | $6.13M |
| Stock-based compensation | $29.27M | $26.07M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.